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ABSTRACT  
Introduction: Pituitary adenomas (PAs), also known as a pituitary neuroendocrine tumours 
(PitNET), are usually benign tumours of the anterior lobe of the pituitary gland and account 
for the third most common intracranial neoplasm. The most common type of pituitary 
adenoma is lactotroph adenoma, in which dopamine agonists are the first-line treatment. 
Nevertheless, in selected cases surgery or even radiotherapy may be required. In the current 
study, we aimed to analyse all patients who underwent surgery due to intrasellar mass in 
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order to evaluate frequency of particular pituitary tumours, clinical diagnosis, and pathology 
findings. 
Material and methods: We retrospectively analysed all cases of patients consecutively 
operated due to intrasellar mass between 1st January 2010 and 31st December 2018 at the 
Department of Neurosurgery, Military Institute of Medicine in Warsaw, Poland.  
Results: Our database included 2348 cases: 1390 women (59.2%) and 958 men (40.8%). The 
mean age for women was 48.4 years (SD ± 15.72; median 49) and for men 50.9 years (SD ± 
14.94; median 53). In our cohort we found: 869 gonadotroph and null cell adenomas, 751 
somatotroph and mammosomatotroph adenomas, 386 corticotroph adenomas, 71 
plurihormonal adenomas, 59 craniopharyngiomas, 44 lactotroph adenomas, 18 purely 
thyrotroph adenomas, and other rare cases of pituitary tumours including one pituitary 
carcinoma metastasising to the liver (corticotroph origin). 
Conclusions: We provide a comprehensive analysis of both clinical and pathological 
findings of the largest cohort of patients operated on for pituitary adenomas in one tertiary 
reference centre. To the best of our knowledge, this is the largest up-to-date published 
analysis in our country. 
Key words: pituitary adenomas; Pas; pituitary neuroendocrine tumours; PitNET; 
retrospective single-centre analysis 
 
Introduction 
Pituitary adenomas (PAs) are usually benign epithelial tumours of the anterior pituitary gland 
and account for 10–15% of all intracranial tumours (in some series reaching over 20%) with 
the prevalence estimated at 1/1000 in the general population [1–4]. Pituitary neuroendocrine 
tumours (PitNET), the new name for pituitary adenomas, was proposed by the International 
Pituitary Pathology Club in 2017. The new terminology is based on heterogenous biological 
and clinical spectrum of neoplasm behaviour.  
Classification of pituitary adenomas is complex and challenging because it can be performed 
based on clinical features such as presence or lack of hormonal activity, pituitary 
insufficiency, visual disturbances, size of the tumour (microadenomas and macroadenomas), 
radiological findings including suprasellar extension, invasiveness to cavernous sinuses, 
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ultrastructural examination, immunohistochemical evaluation, or according to the most 
recently introduced classification with the use of transcriptional factors. 
Hormonally active (functioning) pituitary adenomas are usually detected earlier compared to 
non-functioning pituitary adenomas because they secrete hormones to circulating blood thus 
causing characteristic symptoms for the excess of a particular hormone and may be detected 
in routine blood tests by endocrinologists. They usually cause significant morbidity and 
mortality. Classically functioning pituitary adenomas (also called hormone secreting) are 
divided into: prolactinomas (lactotroph adenomas) exhibiting positive immunostaining for 
prolactin (PRL), somatotroph, mixed GH/PRL, and mammosomatotroph adenomas showing 
positive immune staining for growth hormone (GH)/GH and PRL, respectively; corticotroph 
adenomas positive for adrenocorticotropin (ACTH); thyrotroph adenomas positive for 
thyroid-stimulating hormone (TSH) or gonadotroph adenomas revealing the presence of 
either single hormone — luteinising hormone (LH), follicle-stimulating hormone (FSH), and 
alpha subunit of glycoprotein hormones — or a combination of them. 
It is worth mentioning that overexpression of hormones within pituitary adenoma detected by 
immunostaining is not equivocal with the presence of the hormones in circulating blood [5, 
6]. About 30% of non-functioning pituitary adenomas (NFPAs) do not exhibit hormonal 
staining on IHC, while null cell adenomas account for less than 5% of them. The most 
commonly NFPAs are gonadotroph tumours, which was also validated according to the latest 
classification with the use of transcription factors [7, 8]. 
Almost three decades ago Knosp et al. introduced a classification aimed at evaluating 
pituitary tumour invasiveness by the expansion to surrounding tissues — cavernous sinuses 
[9]. Knosp’s classification includes neither the tumours’ malignant biology nor any known 
marker of invasiveness because it was created regarding solely the anatomical range of the 
tumour. Nevertheless, is still frequently used by radiologists in the assessment of pituitary 
adenoma invasiveness based on magnetic resonance imaging (MRI). We included data 
regarding the Knosp scale for cases, in which such information was available.  
We report a retrospective analysis of a series of surgically removed (by one neurosurgeon) 
pituitary tumours over a nine-year period at the Department of Neurosurgery, Military 
Institute of Medicine in Warsaw (Poland). The presented results were predominantly obtained 
before the introduction of the 2017 World Health Organisation (WHO) classification and 
4 
 
validation of transcriptional factors at our Department of Pathology; therefore, 
immunohistochemical staining for transcriptional factors was not performed. 
 
Material and methods 
Ethical approval was obtained from the Research Ethics Board at the Medical University of 
Warsaw for the purpose of our retrospective analysis. The study was performed in accordance 
with the Helsinki Declaration.  
We enrolled in our retrospective analysis all patients operated on for pituitary mass at the 
Department of Neurosurgery, Military Institute of Medicine (Warsaw, Poland) from 1st 
January 2010 until 31st December 2018. All patients were clinically diagnosed by local 
endocrinologists (from all over the country) and operated by planned surgery due to 
intrasellar mass by one neurosurgeon G.Z. The subsequent pathological diagnosis was 
performed by M.M. from the Department of Pathology and Laboratory Diagnostics, Maria 
Skłodowska-Curie National Research Institute of Oncology (Warsaw, Poland). The 
pathological evaluation included routine immunohistochemical staining on GH, PRL, ACTH, 
β-TSH, β-FSH, β-LH, alpha subunit, and Ki-67 for all pituitary adenomas; moreover, in most 
cases ME was also performed (in every case when the material was preserved). In selected 
cases, immunostaining was extended to the expression of Cam5.2, sstr2A, sstr5, p53, 
MGMT, collagen IV, and others, when appropriate.  
Immunohistochemistry (IHC) 
Tissue samples were fixed in 10% buffered formalin, embedded in paraffin, and routinely 
stained with haematoxylin and eosin. Immunohistochemical staining was performed on 
paraffin-embedded sections according to the labelled EnVision Flex Visualization System 
(K8000, Dako/Agilent) with DAB (3,3′-diaminobenzidine) as chromogen, using antibodies 
available at the time of diagnosis. Currently we are using antibodies against growth hormone 
(GH, dilution 1:500, cat. no. M5-1328-P1), prolactin (PRL, 1:200, cat. no. M5-1362-P1), 
ACTH (1:500, cat. no. M5-1452-P1), β-TSH (1:200, cat. no. M5-1453-P1), β-FSH (1:500, 
cat. no. M5-1449-P1), and β-LH (1:500, cat. no. MS-1448-P1); all antibodies from Thermo 
Fisher Scientific; the glycoprotein α-subunit (dilution 1:1000, cat. no. MCA 1026) from Bio-
Rad, UK; TP53 (DO-7; ready to use, cat. no. IR 616), and Ki-67 (MIB-1 clone, ready to use) 
from Dako; Anti-Cytokeratin (Cam 5.2, cat. no. 790-4555) from Ventana; somatostatin 
5 
 
receptors: sstr2A (dilution 1:1500, cat. no. ss800), and sstr5 (dilution 1:1500, cat. no. ss890) 
from BioTrend. 
The cases in which we did not detect positive staining for any of the hormones, we classified 
as null cell adenomas, and we concluded our final diagnosis based on both IHC and ME 
results. ME allowed us to distinguish whether “null cell adenoma” classified based on solely 
IHC staining was indeed true null cell adenoma or had characteristic ultrastructure for the 
gonadotroph tumours. Thus, our final diagnosis always contributed to the holistic view on the 
results of both methods.  
The staining results of each hormone or hormone’s subunit were recorded, and the 
percentages of immunoreactive cells were graded as follows: (-) all cells negative; (+) > 10% 
cells positive. 
We classified pituitary adenomas as plurihormonal only if they revealed positive hormonal 
staining for hormones originating from different lineage backgrounds (for example 
GH/ACTH, PRL/FSH, TSH/GH, etc.) and the percentage of cells positively stained exceeded 
10%. We did not classify as plurihormonal the double contiguous adenomas [10]. What is 
more, among pituitary adenomas that are classified now as Pit-1 family, often there is 
overexpression of subunit alpha in IHC staining. We did not classify tumours exhibiting the 
solitary additional presence of subunit alpha as a plurihormonal as well. By other authors, 
they were recently classified as unusual plurihormonal pituitary adenomas [11, 12]. 
 
Electron microscopy  
Small pieces of tumour tissues were fixed in 2.5% glutaraldehyde (SERVA; cat. no. 
23116.02), postfixed in 1% osmium tetroxide (SERVA; cat. no. 31253.02), dehydrated in 
ethanol and propylene oxide (Sigma-Aldrich, cat. no. 82320-1L), and embedded in Epon 
(Polysciences, Inc.; Poly/Bed 812, cat. no. 08792-1). Ultrathin sections were counterstained 
with uranyl acetate and lead citrate followed by examination with a Philips CM120 BioTWIN 
transmission electron microscope. Corticotroph and somatotroph adenomas were classified 
on the basis of commonly accepted ultrastructural features, such as densely granulated (DG) 
or sparsely granulated (SG). 
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Statistical analysis 
All statistical calculations were performed using Excel (Microsoft Office), Statistica 
(StatSoft), or GraphPad Prism 6 (GraphPad Software Inc.). Statistical tests: Chi Mann-
Whitney, Kruskal-Wallis, Chi2, or ANOVA were used when appropriate, a cut-off for p-value 
= 0.05 was considered statistically significant. 
 
Results 
The general population of patients with pituitary tumours 
We recorded 2348 cases of patients who underwent surgery from 1st January 2010 to 31st 
December 2018 due to a mass located within the pituitary fossa region. The general 
population consisted of 1390 women (59.2%) and 958 men (40.8%) (Fig. 1). The mean age 
for women was 48.4 years (SD ± 15.72; median 49) and for men 50.9 (SD ±14.94; median 
53).  
In our series we reported according to presurgical diagnosis (based on clinical, biochemical, 
and MRI evaluation) the following numbers of cases: 1007 NFPAs, 621 acromegaly, 392 
Cushing’s disease, 132 prolactinomas, 35 thyrotroph adenomas, and 161 other cases 
(including 71 craniopharyngiomas, 35 Rathke’s cleft cysts, 13 chordomas, and 42 others) 
(Fig. 2). 
 
Figure 1. A pie chart shows the ratio of all patients operated to due to mass located within 
the pituitary fossa region in the years 2010–2018, according to sex 
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Figure 2. A pie chart shows the ratio of all patients operated to due to mass located within 
the pituitary fossa region in the years 2010–2018, according to preoperative clinical diagnosis 
 
 
 
Pathology reports 
Nevertheless, histopathological findings revealed some discrepancies, as shown in Figure 3. 
The final diagnosis based on pathological evaluation was established as listed below: 869 
NFPAs (including both gonadotroph and null cell adenomas), 751 somatotroph and 
mammosomatotroph adenomas together (including silent types), 386 corticotroph adenomas 
(including silent types and Crooke’s cell adenomas), 44 lactotroph adenomas, 18 purely 
thyrotroph adenomas, 71 plurihormonal adenomas, 59 craniopharyngiomas, 22 Rathke’s cleft 
cysts, nine chordomas, 32 normal pituitaries, and other rare cases. There were 11 double 
pituitary adenomas in the analysed group; six clearly separated and five contiguous types. In 
seven patients, somatotroph adenoma coexisted with other adenomas. We recorded only one 
patient with Cushing’s disease and double, clearly separate tumours (coexistence of ACTH-
secreting adenoma and PRL-secreting adenoma diagnosed using BIPSS). Percentages of 
participation for particular types of pituitary tumours are shown in Figure 4. 
Figure 3. A grouped bar graph shows the numbers of cases for each clinical diagnosis and 
well-covered diagnosis for those cases confirmed by pathology reports 
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Figure 4. A pie chart shows the percentage of participation of particular tumour types 
according to histopathological findings. The group ‘other types’ consists of 
craniopharyngiomas, Rathke’s cleft cysts, and chordomas 
 
In our analysis, we recorded four cases of metastases to the pituitary gland (0.17%) 
originating from breast cancers (two patients), thyroid cancer (one patient), and clear cell 
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renal carcinoma (one patient). Other causes of pituitary tumours considered as exceptional 
findings are shown in Table 1.  
Table 1. Selected extremely rare causes of tumours located within the pituitary gland, which 
were collected in our database 
 
During the time of observation, we detected 84 cases of tumour recurrence, with the most 
prevalent relapse for the corticotroph adenomas (including silent types) reaching 25 cases out 
of 84 (29.76%). It accounts for an incidence of 6.48% among corticotroph adenomas. 
The majority of NFPAs revealed positive staining for at least one of the hormones or alpha 
subunits in 92.75% cases (among them gonadotrophs were predominantly found in 91.6%), 
while pure null cell adenomas exhibiting no immunohistochemical staining for hormones or 
their subunits were found only in 63 cases (7.25%). 
Among PAs exhibiting positive staining for hormones and classified as somatotrophs and 
corticotrophs we detected also silent subtypes (55 and 38 cases, respectively). We defined 
silent subtypes according to the literature as tumours without clinical and biochemical signs 
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of the disease, but with apparently present hormonal staining within tumour tissue and 
characteristic ultrastructure in ME. A graph showing the proportion of the silent types in each 
group is presented in Figure 10 (attached in the supplementary section). The difference did 
not reach statistical significance. 
Most of the plurihormonal adenomas were hormonally active in regard to clinical diagnosis: 
only 17 patients were diagnosed as NFPAs, 24 thyrotroph adenomas, 17 acromegaly, eight 
Cushing’s disease, and five lactotroph adenomas.  
 
Age and sex for particular types of pituitary tumours 
Almost in all types of tumours women dominated; the exact distributions of male-to-female 
ratio for each type of pituitary tumour are presented in Figure 5. 
 
Figure 5. Pie charts showing the distribution of males and females according to pituitary 
tumour type. Blue colour represents women, and red colour men 
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The youngest age of occurrence was observed for lactotroph adenomas in women with a 
mean age of 34.2 years (SD ± 12.38; median 29), while for men the mean age was even 
higher than in the general calculated population, at 55.15 years (SD ± 15.89; median 55) 
compared to 50.9 years (SD ± 14.94; median 53), respectively. The total mean age for 
lactotroph tumours was 38.73 years (SD ± 15.64). For acromegaly the mean age was 45.9 
(SD ± 14.14; women 44.8 SD ± 14.4, median 47; men 44.8 SD ± 13.7, median 45), for 
gonadotroph and null cell adenomas 57.19 (SD ± 12.97; women 57.02 SD ± 13.62, median 
58; men 57.35 SD ± 12.56, median 60), for corticotroph adenomas 44.24 (SD ± 16.09; 
women 43.94 SD ± 15.86, median 40.5; men 45.17 SD ± 16.8, median 46), for plurihormonal 
44.28 (SD ±14.82; women 43.7 SD ±15,95, median 38; men 45.07 SD ± 13.38, median 41), 
and for craniopharyngiomas 41.31 years (SD ± 14.31; women 41.33 SD ± 13.89, median 
38.5; men 41.32 SD ± 16.92, median 41).  
A graphical presentation of the age distribution for both sexes (with marked SD values) 
among particular types of tumours according to pathology reports is shown in Figure 6. We 
included cases of normal pituitary finding as well. The overall age distribution among 
selected pituitary tumour types is presented in a time chart (see Fig. 7). 
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Figure 6. Distribution of age according to pituitary tumour types. Black colour means the 
mean age for both sexes marked with a dot, horizontal lines reflect the SD value. Blue colour 
represents woman, and red colour men 
 
 
Figure 7. Age distribution (at the time of surgery) for particular types of pituitary tumours. 
The coloured lines indicate time charts for selected pituitary tumour types: somatotroph 
adenomas, gonadotroph and null cell adenomas, lactotroph adenomas, corticotroph 
adenomas, and other types 
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Knosp scale grades 
We analysed the frequency of occurrence of particular Knosp scale grades for selected 
tumour types, as shown in Figure 8, for the cases in which Knosp scale grades were available 
at the time of data collection. Statistical analysis revealed that those differences were 
statistically significant between all groups (p = 0.0026). 
 
Figure 8. A bar graph illustrates the number of cases for particular tumour types according to 
Knosp scale grades 
 
 
Ki-67 labelling index 
Because most of the cases were collected and diagnosed during the previous classification, 
which distinguished typical and atypical pituitary adenomas characterised by Ki-67 labelling 
index < 3% and ≥ 3%, respectively, we applied this distinction as well. Figure 9 represents 
the frequency of occurrence typical and atypical pituitary tumours including 
craniopharyngiomas. The highest Ki-67 labelling index was present for thyrotroph adenomas, 
somatotroph adenomas, corticotroph adenomas, and gonadotroph and null cell adenomas 
(16.67%, 16.59%, 15.13%, and 14%, respectively). Plurihormonal adenomas were in the vast 
majority (over 92% of cases) characterised by Ki-67 labelling index < 3%. 
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Figure 9. The figure illustrates the Ki-67 labelling index for particular types of pituitary 
tumours. The Ki-67 labelling indices were grouped into categories: < 3% and ≥ 3%. The 
numbers of cases are shown as percentages of participation for selected tumours 
 
 
Discussion 
In our cohort of patients with surgically removed pituitary tumours the most common 
phenotype was non-functioning pituitary adenoma, and among functioning pituitary 
adenomas – somatotroph adenoma, which is in accordance with up-to-date published data 
(Fig. 4) [1, 2, 4]. One needs to remember that in the general population lactotroph adenomas 
are the most frequent type of PAs. In our study pure prolactinomas accounted only for 2% of 
cases, which is due to the fact that the first-line therapy for prolactinomas is an oral 
administration of dopamine agonists. Neurosurgical intervention is required only for: 1) 
tumours resistant to pharmacotherapy, 2) medical therapy such CSF leakage, 3) persistent 
adenoma growth despite pharmacotherapy, 4) pregnancy-related tumour expansion with 
ophthalmological deficits refractory to medical therapy, and 5) pituitary apoplexy. Among 
women, lactotroph tumours were diagnosed at the earliest age and the earliest stage (Fig. 6) 
which is certainly related to symptoms and signs caused by the tumour — infertility and 
menstruation disturbances.  
On the other hand, the reason why prolactinomas were most frequently misdiagnosed in our 
study is that hyperprolactinaemia found in circulating blood (together with adenoma 
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appearance on MRI) may be caused not solely by the prolactin-secreting tumour, but also as a 
consequence of a stalk effect. This means that the tumour (for example non-secreting) rises 
within the pituitary gland or near the stalk and leads to a disrupted connection with the 
hypothalamus, which interferes with the inhibitory effect of its dopaminergic neurons on 
lactotroph cells. As a result, pituitary lactotroph cells, which lack the inhibitory influence of 
hypothalamus, excrete prolactin into circulating blood. Moreover, clinical symptoms 
including amenorrhoea, decreased libido, galactorrhoea, or headaches and infertility are 
identical compared with prolactinomas. Nevertheless, it is worth mentioning that in pure 
prolactinomas the level of prolactin measured in circulating blood correlates with tumour size 
visible on MRI and is much higher than in pseudoprolactinomas [13–15]. 
As to other functioning pituitary adenomas, we found in our cohort of patients that 
acromegaly was the most appropriately diagnosed type of functioning PA (95.17%), which 
was confirmed by pathology reports (Fig. 3). This type of tumour, due to overexpression of 
growth hormone, leads to increased insulin-like growth factor 1 (IGF-1) level and 
characteristic clinical and biochemical features. In our research, acromegaly affected most 
commonly women (62.05% vs. 37.95%) with the mean age of 46.55 years.  
Approximately 95% of acromegaly patients received somatostatin analogues before 
neurosurgery. The therapy usually led to decreased size of pituitary adenomas, but it did not 
affect infiltration to cavernous sinuses. The majority of operated cases in which MRI was 
available were Knosp 0 and Knosp 1 (over 59% of acromegaly cases).  
A study by Park et al. shows that premenopausal women with acromegaly are prone to have 
larger tumours with more aggressive tumour types than men [16]. What is more, Larkin et al. 
reported that histological phenotype of sparsely granulated (SG) somatotroph adenomas, but 
not genotype, refers more accurately to both clinical and biochemical characteristics as well 
as response to the octreotide suppression test [17].  
In all types of pituitary adenomas apart from NFPAs, women dominated (Fig. 1, 5). In 
accordance with the literature, our study shows that NFPAs (here: gonadotroph and null cell 
adenomas) occurred in later decades compared to other PAs independently of sex, with the 
mean age of 57.19 years (for women 57.02 and for men 57.36) [18–20]. What is more, the 
majority of NFPAs revealed Knosp scale grades of 2 and more, which accounted for the most 
advanced stages among all operated pituitary tumours. This fact may be caused by the lack of 
standard diagnostic laboratory tools that help to select patients affected by NFPAs, because 
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this type of PA may rise silently for many years giving no symptoms or unspecific ones 
commonly seen by general practitioners such as headaches, nausea, vomiting — until 
massive enlargement — and then as a macroadenomas they result in visual disturbances by 
the optic chiasm compression due to suprasellar extension. The most recent study by Németh 
K et al. proposed as a useful diagnostic tool monitoring of circulating microRNAs in plasma 
among patients with PAs including NFPAs [21]. However, this study was performed on a 
limited number of NFPA patients and without long-term follow up, thus further 
investigations in this field are crucial.  
In our analysis, we recorded only 84 cases of adenomas recurrence and four cases of 
metastases to the pituitary gland (the most frequent primary origin from breast cancer). 
Sometimes, complete resection of invasive pituitary tumours is unachievable due to deep 
infiltration of the cavernous sinus with wrapping around the cavernous part of the internal 
carotid artery or invasion to adjacent tissues including the skull base. For invasive pituitary 
adenomas, especially hormonally active tumours, which are resistant to the pharmacological 
treatment and intractable for surgical intervention, radiotherapy may be introduced [13, 14, 
22]. Pituitary carcinomas are extremely rare findings defined by the WHO as tumours 
originating from adenohypophyseal cells, having the ability to metastasise either 
craniospinally or to distant parts of the body (e.g. cervical lymph nodes, lungs, liver) [7]. 
Although we detected several extremely rare causes of pituitary tumours (see Tab. 1) in our 
analysis, we recorded only one case of pituitary carcinoma with metastases to the liver in the 
analysed period – it was arising from Crooke’s cell adenoma and is currently treated with 
temozolomide with a good clinical outcome.  
Occasionally, pituitary adenomas elaborate multiple hormones. In our material, we recorded 
only 3% of such tumours — called plurihormonal pituitary adenomas — in contrast to other 
authors, who recorded higher incidences. This fact may be caused by the different 
methodological approaches used in the laboratories and different meanings of 
plurihormonality by itself. We relied on the classification mentioned above in the material 
and methods section, and our plurihormonal group was indeed understood by other authors as 
unusual plurihormonal pituitary adenomas [11, 12]. 
It is worth mentioning that these adenomas may be fully functioning, partially functioning (in 
which only one component is clinically active), or silent. Plurihormonal pituitary adenomas 
are divided into monomorphous and plurimorphous. Plurihormonal Pit-1-positive adenoma 
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(previously called silent subtype 3 adenoma) is very rare and aggressive tumour that is 
identified by unique ultrastructural features [23, 24]. Thus, the International Pituitary 
Pathology Club proposed a new term for pituitary adenoma – pituitary neuroendocrine 
tumour (PitNET) – in order to highlight their unpredictable behaviour [25]. 
Multiple pituitary adenomas are composed of double or more separate tumours or two or 
more different cell types in the same gland. As we showed in results section, we detected 
several reports of double pituitary adenomas. Their incidence is very low, ranging from 0.4 to 
1.3% in large surgical series, and the aetiology remains ambiguous [26]. Preoperative or 
intraoperative precise identification of multiple adenomas is crucial to perform an appropriate 
surgery providing successful outcome [27]. 
To conclude, herein we analysed nine years of experience of one pituitary neurosurgeon. Our 
findings are, in general, coherent with up-to-date published reports. It is worth highlighting 
that, according to the official consensus of the pituitary centres of excellence, pituitary 
tumour removal performed by an experienced neurosurgeon is associated with fewer 
complications. It has been established that there exists a volume-outcome effect for pituitary 
tumours, and the numbers of complications after surgery as well as morbidity and mortality 
are higher with less experienced surgeons but are significantly lower for neurosurgeons who 
performed over 200–500 transsphenoidal operations [28–31]. The Pituitary Society and the 
European Neuroendocrine Association indicated the number of 50 pituitary operations per 
year as the minimal number for dedicated and experienced pituitary neurosurgeons [32–35]. 
It is worth noting that our neurosurgeon performed 2348 operations within nine years, giving 
a mean 260 pituitary surgeries per year. To the best of our knowledge, this is the largest 
retrospective study of surgically removed pituitary tumours to date performed in our country. 
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FIGURE S1. The proportion of silent types of pituitary adenomas among the most 
common hormonally active PAs recorded in our database. The difference of silent type 
occurrence was not statistically significant between two groups measured by the chi-
squared test (p = 0.1419) 
 
 
 
